Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa

GlaxoSmithKline (GSK) logo

GlaxoSmithKline (GSK)

Status and phase

Completed
Phase 3

Conditions

Malaria

Treatments

Biological: Polio Sabin Oral Polio Vaccine (GSK)
Biological: Meningococcal C Conjugate Vaccine
Biological: TritanrixHepB/Hib
Biological: Cell-culture rabies vaccine
Biological: Malaria Vaccine 257049

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT00866619
110021
2012-005716-26 (EudraCT Number)

Details and patient eligibility

About

The purpose of this observer-blind study is to gather key efficacy, safety, and immunogenicity information on GSK's candidate malaria vaccine in infants and children.

Full description

The protocol posting document has been updated due to a protocol amendment dated 23 January 2012. An analysis time point has been added at Month 20. No changes have been made to the protocol endpoints or statistical methods but protocol endpoints will be analysed on data collected up to Month 20 once these data are available. The rationale is to have the full scope of protocol defined efficacy and safety endpoints related to a primary schedule without booster in both age categories followed up for 20 months earlier than at the initially planned study end time point (Visit 34 or Month 32 time point). The protocol posting document was updated due to a protocol amendment dated 10 December 2010 to extend the study until December 2013 for all enrolled subjects (interval: Nov 2013-Jan 2014). Including the extension, the mean follow-up time for subjects from 5-17 months will be during 49 months post dose 1 (range: 41-55), while for subjects from 6-12 weeks, it will be during 41 months post dose 1 (range: 32-48). This study is double-blind during the first part and single-blind during the extension part. An analysis will be conducted at the end of the extension including an evaluation of safety and efficacy against clinical malaria, severe malaria and prevalent parasitemia. The protocol posting document has been updated following the posting of results of the study (January 2015): The study remained double-blind until the end of the extension phase, and the analyses of Month 32 (initial end of study now becoming end of the first part of the study or primary study phase) and of the extension phase were conducted together.

Enrollment

15,459 patients

Sex

All

Ages

6 weeks to 17 months old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

All subjects must satisfy the following criteria at study entry:

  • A male or female child of:5-17 months (inclusive) of age at time of first vaccination,or between 6-12 weeks of age at time of first vaccination and NOT have already received a dose of vaccine against diphtheria, tetanus or pertussis or Hemophilus influenzae type B and must be > 28 days of age at screening.
  • Signed informed consent or thumb-printed and witnessed informed consent obtained from the parent(s)/guardian(s) of the child.
  • Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.

All subjects must satisfy the following criteria at the start of the extension phase:

  • Subjects who were enrolled and who received at least one vaccine dose in the primary trial phase.
  • Subjects who were present for Visit 35 on or before 30 September 2013.
  • Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g. return for follow-up visits) should be enrolled in the study.

Exclusion criteria

The following criteria should be checked at the time of study entry. If any apply, the subject must not be included in the study:

  • Acute disease at the time of enrollment.
  • Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality.
  • Anemia associated with clinical signs or symptoms of decompensation or hemoglobin ≥ 5.0 g/dL.
  • Major congenital defects.
  • History of allergic reactions, significant IgE-mediated events or anaphylaxis to previous immunizations.
  • Children with a past history of a neurological disorder or atypical febrile seizure.
  • Children with malnutrition requiring hospital admission.
  • Children currently meeting the criteria for HIV disease of Stage III or Stage IV severity as defined by the World Health Organization.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to a drug or vaccine that is not licensed for that indication with the exception of studies with the objective of improving the drug treatment or clinical management of severe malaria disease.
  • Use of a drug or vaccine that is not approved for that indication other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Previous participation in any other malaria vaccine trial.
  • Receipt of a vaccine within the preceding 7 days.
  • Any other findings that the investigator feels would increase the risk of having an adverse outcome from participation in the trial.
  • Any other findings that the investigator feels would result in data collected being incomplete or of poor quality

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

15,459 participants in 4 patient groups

GSK257049 [5-17M] Group
Experimental group
Description:
Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.
Treatment:
Biological: Malaria Vaccine 257049
Biological: Meningococcal C Conjugate Vaccine
GSK257049 [6-12W] Group
Experimental group
Description:
Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin vaccines or a booster dose of Menjugate and Polio Sabin vaccines, at Month 20. All vaccines have been administered intramuscularly in the interolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine), except for the Polio Sabin vaccine, which has been given orally.
Treatment:
Biological: Malaria Vaccine 257049
Biological: TritanrixHepB/Hib
Biological: Meningococcal C Conjugate Vaccine
Biological: Polio Sabin Oral Polio Vaccine (GSK)
VeroRab Comparator [5-17M] Group
Active Comparator group
Description:
Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.
Treatment:
Biological: Cell-culture rabies vaccine
Biological: Meningococcal C Conjugate Vaccine
Menjugate Comparator [6-12W] Group
Experimental group
Description:
Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate vaccine co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate and Polio Sabin vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine), except for the Polio Sabin vaccine, which has been given orally.
Treatment:
Biological: TritanrixHepB/Hib
Biological: Meningococcal C Conjugate Vaccine
Biological: Polio Sabin Oral Polio Vaccine (GSK)

Trial contacts and locations

10

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems